Boston Scientific price target raised to $100 from $90 at BofA

BofA raised the firm’s price target on Boston Scientific (BSX) to $100 from $90 and keeps a Buy rating on the shares. The firm, which sees Boston Scientific having “best in medtech growth,” says a higher multiple reflects the firm’s higher confidence in the company’s growth outlook and the durability of its double digit revenue growth. Boston Scientific has “one of the fullest pipelines in medtech and much of the revenue growth is margin accretive,” the analyst added. Published first on TheFly –